Table A6.
Main comorbidities from primary studies on respiratory syncytial virus (RSV) vaccine. Note = COPD, chronic obstructive pulmonary disease.
| Study | Vaccinated (No.) |
Placebo (No.) |
COPD | Asthma | Congestive Hearth Disease |
|||
|---|---|---|---|---|---|---|---|---|
| Vaccinated (n./N., %) |
Placebo (n./N., %) |
Vaccinated (n./N., %) |
Placebo (n./N., %) |
Vaccinated (n./N., %) |
Placebo (n./N., %) |
|||
| Ison et al. [48] | 12,470 | 12,503 | 1131 (9.07%) |
1113 (8.90%) |
1193 (9.57%) |
1113 (8.90%) |
398 (3.19%) |
403 (3.22%) |
| Walsh et al. [52] | 17,215 | 17,069 | 960 (5.46%) |
978 (5.58%) |
- | - | 53 (0.30 %) |
51 (0.29%) |
| Wilson et al. [51] | 17,734 | 17,679 | 1012 (5.88%) |
1080 (6.33%) |
1541 (8.95%) |
1508 (8.83%) |
293 (1.70%) |
307 (1.80%) |
| Falsey et al. [82] | 2891 | 2891 | 219 (7.58%) |
208 (7.19%) |
266 (9.20%) |
250 (8.65%) |
58 (2.01%) |
54 (1.87%) |